1. To learn about major EU-funded research projects related to cancer imaging in which EIBIR is a partner.
2. To appreciate the impact these projects will have on cancer diagnosis and care.
3. To understand the role of the European Institute for Biomedical Imaging Research (EIBIR) in such projects.
The European Institute for Biomedical Imaging Research (EIBIR) is an organization aiming to coordinate research in, and innovation of, biomedical imaging technologies within Europe and support the dissemination of knowledge with the ultimate goal of improving prevention, detection, diagnosis, and treatment of disease. EIBIR promotes networking activities within Europe and ensures the pooling of resources among members to promote a culture of cooperation between them. EIBIR also generates publicity concerning new opportunities for access, provide dissemination of knowledge, and training courses for potential users.
In the competitive landscape of European funding, EIBIR has enabled numerous consortia to successfully apply and perform large collaborative research projects. Recently within the Horizon 2020 framework EIBIR is supporting a number of innovative ventures related to cancer research. The expertise that the office has built up over the past years did not only provide a competitive edge in obtaining funding, but will also guarantee the dissemination of the promising results of these projects. This session should provide information on how the EIBIR services can help the researchers in their endeavors and give an overview of three successfully running projects aiming to have an impact in cancer diagnostics and therapy.
1. To learn about the application of diffuse optics to human tissue.
2. To understand the technology of LUCA.
3. To learn about the project's status and its initial results.
Near-infrared diffuse optics is receiving increasing interest in cancer diagnostics for its capability to measure unique and complementary parameters based on hemodynamics (microvascular blood flow, blood oxygen saturation and blood volume), tissue structure (cell density, size) as well as water and other chromophore concentrations in combination with established imaging technologies in a non-invasive, relatively fast and safe procedure. After description of the background physics, the basics of the technology, and different approaches for probe development, a particular focus will be given to hybrid technologies that combine diffuse correlation spectroscopy (DCS) and diffuse optical time resolved spectroscopy (TRS) for biomedical applications. Finally, I will introduce and report the present status of LUCA (http://www.luca-project.eu), a European project, aiming at development and validation of a combined ultrasound- optical prototype for thyroid cancer diagnostics.
1. To learn about a multicentre clinical trial of the project's hybrid MR/PET insert.
2. To understand how the trial will validate the project's ground-breaking MR/PET technology.
3. To appreciate the complexity of undertaking such a multicentre clinical trial at European level.
With a consortium of ten partners from across Europe, including major universities, research institutes, SMEs and major industry corporations, the HYPMED project brings together a wide range of expertise. In this project “Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer (HYPMED)”, we aim to develop a hybrid system combining MRI and PET that facilitates earlier diagnosis of breast cancer and personalized therapy control. To achieve this, we are designing and testing a combined PET-radiofrequency (RF) insert that can be connected to a conventional clinical MR scanner, transforming the device into a high-resolution PET/MRI hybrid system. This PET-RF insert can be used to identify even the smallest breast cancer foci and better characterize the cancer, as well as its response to therapy. Another key benefit of this technology for patients is that the radiation dose of the new technology will, unlike other PET-MRI examinations, be comparable to the low dose of a regular digital mammogram. Apart from merely diagnosing the presence or absence of breast cancer, HYPMED will improve the non-invasive biological classification of breast cancers, in other words it will improve the assessment of its aggressiveness, therefore facilitate better selection of appropriate treatments. In a bench to bedside approach HYPMED includes several work packages spanning the spectrum from designing to clinical testing.
1. To understand how the system developed by the project will combine optical methods with ultrasound.
2. To appreciate how the technology developed by the project will improve the ability to differentiate between benign and malignant lesions.
Due to the high false-positive risk of mammography, there is an unmet clinical need for higher specificity in breast cancer imaging following screening. Photonics and ultrasound-based imaging are both non-invasive and have, to some extent, been proven effective in characterising breast lesions, discriminating malignant from benign ones. However, up to now, no individual technique proved to be adequate in replacing conventional methods. The EU-funded research project SOLUS will develop innovative photonic components, combining photonics with ultrasound techniques, and clinically validate the resulting multi-modal approach in breast cancer patients. To meet the clinical need, SOLUS develops novel pulsed laser sources and high dynamic range single-photon detectors, providing unprecedented sensitivity and depth penetration, making diffuse optical tomography feasible in real clinical settings. For the first time, this approach will allow; (1) a comprehensive quantitative characterisation of breast tissue, including composition (water, lipid, collagen content) and functional blood parameters as provided by diffuse optical tomography; (2) morphologic information from B-mode ultrasound imaging; and (3) mechanical parameters (stiffness) from shear wave elastography. Subsequent multi-parametric data analysis, using new reconstruction algorithms, allows high specificity in the discrimination between borderline malignant and benign breast lesions. SOLUS is a trans-disciplinary, 48-month project that brings together 9 partners (industry, academia and hospitals) from 5 countries.
1. To learn about EIBIR and its services for researchers.
2. To understand project management and dissemination activities of European projects.
3. To appreciate how EIBIR can support your research project.
Due to shrinking national research budgets, European researchers more frequently apply for EU funding sources. However, navigating through the rules and regulations of large EU projects while simultaneously carrying out innovative research with partners from across Europe can be challenging. Thus, multidisciplinary and multinational consortia require professional project management to ensure the successful accomplishment of their project goals. The European Institute for Biomedical Imaging Research, EIBIR, is a non-profit organisation founded by the European Society of Radiology and supports researchers and industry partners in the coordination of biomedical imaging research throughout Europe and beyond. EIBIR offers expert advice, professional project management and coordination, dissemination and exploitation services for dedicated international collaborative research projects. The EIBIR services also include advice on funding opportunities, identifying consortium partners and proposal writing support by a team of experienced writers with knowledge of the European Commission's requirements. Partners also benefit from EIBIR`s established, extensive network for dissemination. Through the large and diverse landscape of network members, shareholder organisations, industry partners and media contacts the conducted research is be widely and rapidly communicated. EIBIR is currently partner and/or coordinator of seven projects that are funded under Horizon 2020, the biggest EU Research and innovation programme. The offered support relieves researchers of the administrative burden, allowing them to focus on the scientific aspects and thereby ensuring the best possible outcome for the project.